{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 207, "pageCount": 415, "prevPage": 206, "nextPage": 208, "slideType": "testimonial", "function": "expose_contradiction", "density": "dense", "nDataPoints": 0, "notes": "The slide presents a Q&A transcript excerpt highlighting potential fraud and competitive threats.", "elementsJson": [ "paragraph", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/207", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-207", "components": [ { "bbox": null, "kind": "callout", "text": "I do believe it was slightly manipulated...Off-label, certainly people could use it...you’re completely right. If this is really such a good drug, people can use diazoxide and suspension exactly the same way for pennies on the dollar.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b2a8-196d9bfe5bdf", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.28, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "paragraph", "text": "A former employee who played a key role in Soleno’s clinical trial program confirmed our view that the data in the PK paper was manipulated – the ex-employee diplomatically phrased it as “slightly manipulated” – and concurred that off-label substitution by generic diazoxide suspension is a key threat to Vykat – “I agree with you 100%, and I agree with your take on Neil Cowen’s PK paper...I do believe it was slightly manipulated...off-label, certainly people could use it...you’re completely right...if this is really such a good thing, people can use diazoxide and suspension exactly the same way for pennies on the dollar.”", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f5b80d29-6aba-468f-9a81-1be5e241841a", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.48, "w": 0.86, "x": 0.07, "y": 0.42 }, "kind": "quote", "text": "Soleno PK paper was manipulated; generic liquid suspension is perfectly substitutable with Vykat\nQ: “There's a PK paper from Neil Cowen a few years ago — you may have seen it — that compares the cMax, tMax, etc. of DCCR with oral suspension. I had a pharmacologist who looked at that data and said, look, these things are functionally identical. They manipulated the data for the oral suspension in the PK paper to make it look like it has a higher peak. All you need is a slightly different dose of oral suspension to achieve essentially the same steady state plasma concentration in a few days as with DCCR. The drug has a very long half-life. And it seems to me that aside from a safety signal coming out, the biggest threat to the company is that doctors are going to figure out that you can just prescribe generic diazoxide oral suspension off-label without all the problems of a tablet. What is your take on oral suspension, that formulation versus DCCR? It seems disingenuous to me.”\nA: “I agree with you 100%, and I agree with your on your take on Neil Cowen’s PK paper. I do believe it was slightly manipulated. Unfortunately, our system is such that if you didn't test diazoxide as such in Prader-Willi, you can't really have an indication for it. Off-label, certainly people could use it...you’re completely right. If this is really such a good drug, people can use diazoxide and suspension exactly the same way for pennies on the dollar.” – Ex-senior Soleno employee #1, key role in clinical trial program", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f9309876-fc64-4827-8fbc-950a49f4f72a", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "I agree with you 100%, and I agree with you on your take on Neil Cowen’s PK paper. I do believe it was slightly manipulated...Off-label, certainly people could use it...you’re completely right. If this is really such a good drug, people can use diazoxide and suspension exactly the same way for pennies on the dollar. — Ex-senior Soleno employee #1, key role in clinical trial program", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b2a8-1e742e86c414", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.3, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "580d1ed0-9470-4f9f-a2fb-eff29610f932", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [ { "name": "fraud-exposure", "slug": null, "matchId": "2ee9a4a2-48b3-4cd7-8435-4318218b04de", "evidence": "The slide explicitly claims data manipulation in a clinical trial paper.", "confidence": 0.9 } ], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }